1 Troglitazone, an insulin-sensitizing agent shown to improve cardiac function in both experimental animals and patients with diabetes, inhibits voltage-dependent L-type Ca 2+ currents (I Ca,L ) in cardiac myocytes, which may underlie its cardioprotective eects. However, inhibition by troglitazone of I Ca,L in diabetic cardiac myocytes has not been characterized. 2 Using whole-cell voltage-clamp techniques, I Ca,L was measured in ventricular myocytes isolated from 4 ± 6 weeks streptozotocin (STZ)-induced diabetic rats and age-matched control rats. 3 Under control conditions with CsCl internal solution, diabetic myocytes did not dier from control myocytes in membrane capacitance, current density or voltage-dependent properties of I Ca,L . 4 Troglitazone decreased amplitude of I Ca,L in both control and diabetic myocytes in a concentration-dependent manner. This inhibition was more potent in diabetic than in control myocytes; half-maximum inhibitory concentrations of troglitazone measured at a holding potential of 750 mV were 4.3 and 9.5 mmol l
Introduction
An explosive increase has occurred in our understanding of how diabetes mellitus increases the risk of cardiac dysfunction. This eect can occur independently of coronary atherosclerosis, hypertension, and valvular disease (Hamby et al., 1974; Kannel et al., 1974; Regan et al., 1977) . A variety of abnormalities in contraction and relaxation have been identi®ed in the streptozotocin (STZ)-induced diabetic heart (Fein et al., 1980; Penpargkul et al., 1980) . In this regard, intracellular Ca 2+ overload may underlie subcellular mechanisms responsible for these abnormalities (Teshima et al., 2000; Kjeldsen et al., 1987; Makino et al., 1987; Pierce & Dhalla, 1985; Penpargkul et al., 1981) .
Troglitazone, a thiazolidinedione derivative, is an oral hypoglycaemic agent that reduces insulin resistance (Fujiwara et al., 1988; Suter et al., 1992) . Troglitazone treatment reportedly improves cardiac function in STZ-induced diabetic rats and also in diabetic patients (Shimabukuro et al., 1996; Chazzi et al., 1997) . Although the precise mechanisms responsible for cardioprotective eects of this agent remain unclear, inhibition of voltage-dependent L-type Ca 2+ currents (I Ca,L ) may be involved. In vascular smooth muscle cells, thiazolidinediones including troglitazone reduce the amplitude of I Ca,L (Zhang et al., 1994; Song et al., 1997; Nakamura et al., 1998) , an eect also demonstrated in cardiac myocytes (Nakajima et al., 1999; Katoh et al., 2000; Ikeda & Watanabe, 1998) . Because treatment with verapamil or diltiazem lessens cardiac dysfunction in diabetes (Afzal et al., 1988; 1989; Fein et al., 1991) , cardioprotective eects of troglitazone could be explained in terms of antagonism of I Ca,L . However, no reports have described the inhibitory action of troglitazone on I Ca,L in diabetic myocytes.
In the present study, the whole-cell voltage-clamp technique was used to compare eects of troglitazone on I Ca,L in isolated rat ventricular myocytes in STZ-induced diabetes with eects in control rat myocytes.
Methods

Induction of diabetes
Male Wistar King A rats (8 weeks old, 250 ± 300 g) were anaesthetized with diethyl ether and then received a single injection of STZ (60 mg kg All experimental procedures were performed in accordance with the guidelines of the Physiological Society of Oita Medical University, Japan, for the care and use of laboratory animals.
Cell isolation
Four to 6 weeks after STZ or vehicle injection, single ventricular myocytes from the diabetic rats and age-matched control rats were isolated using an enzymatic dissociation procedure as previously described (Taniguchi et al., 1981) . Brie¯y, the animals were heparinized (500 IU kg 71 , i.p.) and anaesthetized with sodium pentobarbital (100 mg kg 71 , i.p.). Hearts were removed quickly, and the aorta was cannulated and perfused by a Langendor perfusion apparatus with normal Tyrode's solution (see below). The heart was then perfused with nominally Ca 2+ -free Tyrode's solution for 5 min at a rate of 12 ml min 71 followed by perfusion with the same solution containing collagenase (0.13%, w v
71
; Wako Pure Chemical, Osaka, Japan) and type XIV protease (0.005%, w v
; Sigma Chemical, St. Louis, MO, U.S.A.) at 378C. Twenty to 25 min later the heart was perfused with recovery solution. The right ventricle was dissected, and cells were mechanically dispersed and stored in recovery solution at 48C. This procedure consistently yielded an acceptable number of quiescent, relaxed ventricular cells. The cell yield and viability in the Tyrode's solution were not much dierent among both groups.
Solutions and chemicals
The Tyrode's solution contained the following (as mmol l ): CsCl 140, tetraethylammonium chloride (TEA-Cl) 10, EGTA 10, BAPTA 2, Na 2 ATP 3, Na 3 GTP 0.1, MgCl 2 1, and HEPES 5 (pH adjusted to 7.3 with CsOH). Troglitazone, obtained from Sankyo Co Ltd, Japan, was dissolved in DMSO to give a stock solution of 30 mmol l 71 to 300 mmol l
71
. The ®nal concentration of DMSO in the bathing solution was 0.1%. Before experiments, this concentration of DMSO was con®rmed not to signi®cantly in¯uence I Ca,L .
Electrophysiological recordings
Membrane currents were measured at room temperature (22+18C) using the whole-cell con®guration of the patchclamp technique (Hamil et al., 1981) . Myocytes were allowed to settle in the bath for 5 min before being superfused with external solution at a rate of 1 ml min
71
. Heat-polished patch electrodes with a tip resistance of 2 to 6 MO were used. After obtaining a gigaseal, a suction pulse was applied to establish the whole-cell mode. Command pulses were delivered and data were acquired with an EPC-8 patch-clamp ampli®er controlled by the PULSE software (HEKA, Lambrecht, Germany) connected to a Power Macintosh G4 computer (Apple Computer, Cupertino, CA, U.S.A.). High-resolution currents were low-pass ®ltered at 3 kHz, acquired at a sampling rate of 10 kHz, and stored on a hard disk for oline analysis.
Data analysis and statistics
The amplitude of I Ca,L was de®ned as the dierence between the peak inward current and the current at the end of the test pulse. Initial data were obtained after the amplitude of I Ca,L had stabilized within 10 min after the rupture of the membrane. The amplitude of I Ca,L diminishes as a function of time during patch-clamp recording, a phenomenon termed run down' (Belles et al., 1988) . In the experiments presented here, the rate of I Ca,L run down was similar between control and diabetic myocytes and resulted in 510% reduction in peak current by the 10 min recording period (5.7+1.2%, n=30 vs 5.9+1.2%, n=30, P=ns). Thereafter, the eects of troglitazone on I Ca,L could be investigated for 15 ± 20 min. At the start of each experiment, the series resistance was compensated. For o-line data analysis, IGOR PRO software (WaveMetrics, Lake Oswego, OR, U.S.A.) was used. Data are presented as the mean+s.e.m. Statistical signi®cance was determined with the unpaired Student's t-test in conjunction with the Newman-Keuls test where applicable. Dierences were considered signi®cant at the level of P50.05.
Results
Body weight and fasting plasma glucose concentrations of experimental animals
The basic characteristics of STZ-induced diabetic rats and age-matched control rats used in the present study are summarized in Table 1 . Body weight was lower (P50.01) and plasma glucose concentrations were higher (P50.01) in the diabetic rats than in control rats.
Cell capacitance, current densities and current-voltage relationships of I Ca,L
In each voltage-clamp experiment, membrance capacitance was measured immediately after disruption of the membrane patch. Membrane capacitance of control myocytes did not dier signi®cantly from that of diabetic myocytes (196.1+15.1 pF, n=17 vs 175.7+9.7 pF, n=28, P=ns). Membrane currents were elicited by stepwise voltage changes of 300 ms duration from an initial 750 mV to a range between 760 and +60 mV. The changes were applied in increments of 10 mV at 0.2 Hz frequency ( Figure 1A ). Transient inward currents were elicited in control and diabetic myocytes, peaking within 10 ms after onset of depolarization and gradually declining, maximal peak current occurred at a potential of +0 mV. The inward current was completely blocked by Cd 2+ at 0.1 mmol l 71 (data not shown), indicating that it consisted of I Ca,L . Maximum densities of I Ca,L were not signi®cantly dierent between control and diabetic myocytes (7.5+0.4 pA pF 
Steady-state inactivation and activation of I Ca,L
Steady-state inactivation and activation of I Ca,L was determined in ®ve control myocytes and ®ve diabetic myocytes. For estimating steady-state inactivation, a double-pulse voltage-clamp protocol was used. After establishing conditioning holding potentials at dierent voltage levels between 760 mV and +60 mV for 1 s, a test pulse to +0 mV with a duration of 300 ms was applied to elicit I Ca,L . Normalized current amplitudes (I/I max ) were plotted against conditioning holding potentials. A steady-state inactivation curve was drawn by ®tting the data to the Boltzmann distribution, I/I max =1/{1+exp[(V-V h )/k]}, with I/I max representing the relative current amplitude compared with the maximum current amplitude; V, the conditioning holding potential; V h , the potential required for half-inactivation of the current; and k, the Boltzmann coecient. The steadystate inactivation curves of I Ca,L were similar between control and diabetic myocytes ( Figure 1C and Table 2 ).
Conductance (G) was calculated using the equation, G=I peak /(V-V rev ), with I peak as the peak amplitude of the current; V, the test potential; and V rev , the reversal potential. The potential at zero current level, tentatively used as the reversal potential, was estimated from the current-voltage curve or determined in some cases by extrapolating the current-voltage relationship until the inward current became outwardly directed. For estimating steady-state activation, I Ca,L conductances were plotted against test potentials. The derived activation curve was ®tted to data with a Boltzmann equation, G/G max =1/{1+exp[(V 1/2 -V)/k]}, with G/G max as relative conductance normalized to the maximal conductance; V 1/2 , the potential required for half-activation of the current; and k, the Boltzmann coecient. Steady-state activation curves of I Ca,L nearly overlapped between control myocytes (V 1/2 =710.7+1.4 mV, k=6.2+0.6 mV, n=5) and diabetic myocytes (V 1/2 =711.5+1.5 mV, k=6.0+0.3 mV, n=5, Figure 1D ). 
The time course of inactivation of I Ca,L was determined by analysis of the decay phase of current traces. Myocytes were held at 750 mV, and command pulses to +0 mV were applied at 0.2 Hz. Best ®t was obtained with an equation including a sum of two exponentials plus a constant expressed as A fast exp(7t/t fast )+A slow exp(7t/t slow )+A 0 , with t and A as the time constant and the initial amplitude of the two components subscripted fast and slow, respectively; and A 0 , the amplitude of the time-independent component. Pooled mean values for the fast (t fast ) and slow (t slow ) time constants of inactivation were similar in control and diabetic myocytes ( Table 3) .
Effects of troglitazone on I Ca,L
The eects of troglitazone on I Ca,L were compared between control and diabetic myocytes. Figure 2 represents typical examples. Cells were held at 750 mV, and command pulses (300 ms in duration) to +0 mV were applied at 0.2 Hz. Application of troglitazone at 3 mmol l 71 began to reduce the amplitude of I Ca,L within 30 s in both control and diabetic myocytes, but the decline of the current amplitude was greater in latters. In both control and diabetic myocytes, washout of troglitazone caused partial recovery of I Ca,L . During 120 s application of troglitazone at 3 mmol l
71
, the per cent inhibition of I Ca,L was greater in diabetic myocytes than in control myocytes (34.5+4.5%, n=11 vs 22.2+2.4%, n=14; P50.05). Concentrationdependent inhibition of I Ca,L by troglitazone is shown in Figure 3 . The concentration-dependent curve of I Ca,L to troglitazone was signi®cantly shifted to the left in diabetic myocytes compared with control myocytes (P50.01). The concentration of drug giving half-maximum inhibition (IC 50 ) measured at a holding potential of 750 mV was 9.5 mmol l 71 in control myocytes, but only 4.3 mmol l 71 in diabetic myocytes. Figure 4 shows the eects of troglitazone on the current-voltage relationships of I Ca,L in four myocytes from each group. Troglitazone at 5 mmol l 71 reduced the amplitude of I Ca,L at any command voltage without aecting the voltage dependence of I Ca,L in either control or diabetic myocytes. The reversal potential for I Ca,L was not altered signi®cantly by troglitazone in control or diabetic myocytes (data not shown).
Effects of troglitazone on steady-state inactivation and inactivation time course of I Ca,L Figure 5 shows the voltage dependencies of steady-state inactivation of I Ca,L recorded in control and diabetic myocytes in the absence and presence of 5 mmol l 71 of troglitazone. Troglitazone only slightly shifted the steadystate inactivation curve to the left in both groups of myocytes ( Table 2) . Values of t fast and t slow in the presence of 5 mmol l 71 of troglitazone were not signi®cantly dierent between control and diabetic myocytes (Table 3) .
Discussion
Main findings
The main ®ndings of the present study are that while troglitazone rapidly inhibited I Ca,L in a concentrationdependent manner in both control and STZ-induced diabetic ventricular myocytes, the inhibitory eect was stronger in the latter myocytes. Troglitazone did not in¯uence the voltagedependent properties of I Ca,L in control and diabetic myocytes.
Effects of diabetes on I Ca,L
In the absence of troglitazone, control and diabetic myocytes showed no signi®cant dierences with respect to membrane capacitance, current densities, or any voltage-dependent properties of I Ca,L . The eects of diabetes on current density of I Ca,L remain to be controversial. Our ®ndings are in agreement with those reported by Jourdon & Feuvray (1993) . However, Wang et al. (1995) and Chattou et al. (1999) reported that the density of I Ca,L was reduced in ventricular myocytes isolated from diabetic rats. The eect of diabetes on I Ca,L may depend on the duration of diabetes. It might be inferred that the longer duration of the diabetic state, the more severe is the depression of the I Ca,L likely to develop. Alternatively, the dierences in the basal phosphorylation state of the myocardial I Ca,L between diabetic and control myocytes may be involved. It is also possible that each study was performed under dierent experimental conditions, leading to the dierent results. Effects of troglitazone on I Ca,L in control and diabetic myocytes
In the present study, troglitazone inhibited I Ca,L immediately after addition to control and diabetic myocytes without any modi®cation of the kinetics or voltage dependence of the current. Nakajima et al. (1999) also demonstrated that the inhibitory eect of troglitazone on I Ca,L in guinea-pig atrial myocytes was neither voltage-dependent nor use-dependent. Together with our observations, it is suggested that the inhibitory action of troglitazone on I Ca,L could be a direct eect. As presented in Figure 2C ,D, the troglitazone slowly inhibited I Ca,L . Because washout of troglitazone caused partial recovery of I Ca,L , we believe that the gradual decrease in I Ca,L was not due to the rundown. In the previous studies (Katoh et al., 2000; Nakajima et al., 1999; Nakamura et al., 1998) , the inhibition of I Ca,L by troglitazone was also reported to be slow. The precise binding mechanisms of troglitazone remain to be elucidated. In the present study, inhibition by troglitazone of I Ca,L was enhanced in STZ-induced diabetic myocytes. In related observations, increased sensitivity of the diabetic heart to Ca 2+ channel antagonists has been demonstrated (Lee et al., 1992; Heijnis et al., 1991) . In isolated perfused hearts in STZinduced diabetic hearts, several L-type Ca 2+ channel antagonists were reported to cause more depression of contractile force than they caused in control hearts (Lee et al., 1992; Heijnis et al., 1991 . Lee et al. (1992 found the number of L-type Ca 2+ channels, as measured by 3 Hnitrendipine binding, in the myocardial membrane to be decreased in STZ diabetic rats, while the channels showed increased anity for antagonists. Because no dierence was observed in I Ca,L current density in the present study, enhanced inhibition of I Ca,L in STZ-induced diabetic myocytes may be explained by increased anity of troglitazone for L-type Ca 2+ channels. This hypothesis may be supported by a recent report demonstrating that relative responsiveness of I Ca,L to dihydropyridines was much higher in vascular smooth muscle cells isolated from STZ-induced diabetic rats compared to control rats (Wang et al., 2000) .
In our unpublished data using a nystatin-perforated patch method, the inhibition of I Ca,L was also greater in diabetic myocytes than in control myocytes when 3 or 10 mmol l 71 troglitazone was applied. However, the inhibitory eect was , troglitazone also inhibited I Ca,L more eectively in STZ-diabetic myocytes than in control myocytes. The eects of troglitazone under the condition with Ca 2+ overloading should be assessed in future studies.
Cardioprotective effects of troglitazone in diabetes
In diabetic myocytes, intracellular Ca 2+ homeostasis is impaired by several mechanisms likely to contribute to intracellular Ca 2+ overload (Teshima et al., 2000; Kjeldsen et al., 1987; Makino et al., 1987; Pierce & Dhalla, 1985; Penpargkul et al., 1981) . Hyperglycaemia may play a key role in these disturbances; for instance, function of cardiac sarcoplasmic reticulum Ca 2+ ATPase is depressed in STZinduced diabetic heart, leading to prolonged relaxation (Penpargkul et al., 1981) . We recently demonstrated that expression of sarcoplasmic reticulum Ca 2+ ATPase mRNA was diminished in STZ-induced diabetic rats and that expression was restored by normalization of plasma glucose level with insulin treatment (Teshima et al., 2000) . Ren et al. (1996) 
Limitations
There are several limitations in the present study. First, we evaluated the eects of troglitazone on I Ca,L using 4 ± 6 weeks STZ-induced diabetic rats. Because Wang et al. (1995) reported that I Ca,L was signi®cantly smaller in 24 ± 30 weeks STZ diabetic rats compared to age-matched controls, further studies are necessary to assess the eects of troglitazone using diabetic rats with longer duration of diabetes. Second, our hypothesis that troglitazone may reduce intracellular Ca 2+ overload is purely speculative. To prove this, measurements of cytosolic Ca 2+ must be made. Lastly, experiments using Ba 2+ instead of Ca 2+ are required to support our hypothesis that inhibitory action of troglitazone on I Ca,L is a direct eect.
Relevance
Troglitazone is an insulin-sensitizing agent, used to treat patients with type 2 diabetes mellitus who show hyperinsulinemia (Suter et al., 1992) . The present study used STZinduced diabetic rat, which is an insulin-de®cient diabetic model. The choice of model, then, may be a limitation of the present study. However, some bene®cial eects of troglitazone may represent compensation for adverse eects of hyperglycaemia (Ren et al., 1996) . Therefore, our observations suggest that troglitazone might bene®t for a wide variety of hyperglycaemic patients. In the present study, the IC 50 of troglitazone for I Ca,L in diabetic myocytes was 4.3 mmol l
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, which is near the established therapeutic plasma concentration (Shibata et al., 1993) . Thus, the inhibitory action upon I Ca,L by troglitazone may be clinically important.
Conclusions
In the present study, troglitazone inhibited I Ca,L more eectively in STZ-induced diabetic ventricular myocytes than in age-matched control myocytes, possibly because of increased sensitivity to troglitazone of L-type Ca 2+ channels in diabetic myocardium. These results suggest that troglitazone may be useful in preventing diabetic cardiac dysfunction because of actions that reduce intracellular Ca 2+ overload.
